Geneos Wealth Management’s Core Laboratories CLB Stock Holding History

Geneos Wealth Management’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-105	Closed	-$7K	–	2496
2019 Q1	$7K	Buy	105 +1	+1%	+$67	﹤0.01%	1936
2018 Q4	$6K	Hold	104	–	–	﹤0.01%	1915
2018 Q3	$12K	Buy	104 +1	+1%	+$113	﹤0.01%	1776
2018 Q2	$13K	Hold	103	–	–	﹤0.01%	1599
2018 Q1	$11K	Hold	103	–	–	﹤0.01%	1599
2017 Q4	$11K	Buy	103 +1	+1%	+$100	﹤0.01%	1592
2017 Q3	$10K	Hold	102	–	–	﹤0.01%	1561
2017 Q2	$10K	Sell	102 -24	-19%	-$2.59K	﹤0.01%	1523
2017 Q1	$14K	Buy	126 +13	+12%	+$1.51K	﹤0.01%	1361
2016 Q4	$13K	Buy	113 +1	+0.9%	+$111	﹤0.01%	1343
2016 Q3	$12K	Buy	112 +12	+12%	+$1.38K	﹤0.01%	1296
2016 Q2	$12K	Hold	100	–	–	﹤0.01%	1268
2016 Q1	$10K	Buy	+100	New	+$10.4K	﹤0.01%	1298

Other funds holding CLB

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geneos Wealth Management's CLB Position: Q2 2019 in Review

Geneos Wealth Management sold out of Core Laboratories (CLB) in Q2 2019, closing a stake of 105 shares — an estimated $7K sold.

Geneos Wealth Management first reported a position in CLB in Q1 2016 and held it in 13 quarters. The position peaked at $14K in Q1 2017. 304 funds tracked by Wall St. Rank hold CLB as of Q2 2019.

Geneos Wealth Management reported no remaining Core Laboratories position as of Q2 2019 after selling out during the quarter.
Geneos Wealth Management sold 105 Core Laboratories shares in Q2 2019, an estimated $7K.
Geneos Wealth Management first reported a position in Core Laboratories in Q1 2016 and held it in 13 quarters.
Geneos Wealth Management's Core Laboratories position peaked at $14K in Q1 2017.
304 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2019.

Based on Geneos Wealth Management's 13F filing for Q2 2019, filed 7 Sep 2021.